Anacetrapib

Star0

DB06630InvestigationalSmall molecule

Investigated for use/treatment in hyperlipidemia.

Mechanism: Pharmacologically active on Cholesteryl ester transfer protein
Curator reviewed
Primary indication: Investigated for use/treatment in hyperlipidemia.Curator reviewed
Formula / weight: C₃₀H₂₅F₁₀NO₃ · 637.518 g/mol (avg)
Code names: MK-0859

Resolves to

Compound

UNIIP7T269PR6SCAS875446-37-0ChEMBLCHEMBL1800807

Structure

InChIKeyMZZLGJHLQGUVPN-HAWMADMCSA-NSMILESCOC1=CC(F)=C(C=C1C1=CC=C(C=C1CN1[C@@H](C)[C@H](OC1=O)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C

Targets

P11597CETP

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Anacetrapib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account